CHICAGO--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ: INGN) and the Company’s clinical collaborators today reported updated Phase 2 data demonstrating a significant correlation between abnormal p53, tumor responses and increased survival following ADVEXIN® therapy in patients with recurrent squamous cell carcinoma of the head and neck. The data (Abstract #6057) were presented today at the annual meeting of the American Society of Clinical Oncology in Chicago.
